SCHEMBL6624700

SCHEMBL6624700

CCCCOc1ncc(I)cc1C(N)=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.37
CYP3A4 P08684 3/20 0.33
LMNA P02545 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
MEN1 O00255 1/20 0.33
NR1I2 O75469 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRA2A P08913 1/20 0.33
MAPT P10636 1/20 0.33
OPRK1 P41145 1/20 0.33
HTR2B P41595 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KMT2A Q03164 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CNR1 P21554 1/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6625524 0.85 MEN1 (0.44) CNR2CYP3A4LMNACA12CA1
SCHEMBL6624693 0.81 KDM4E (0.45) CNR2MEN1KMT2ARAB9AKDM4E
Formic Acid SCHEMBL6624114 0.80 CNR2 (0.36) CNR2CYP3A4LMNACA12CA1
SCHEMBL1505647 0.78 TSHR (0.54) CYP3A4LMNAKDM4ETSHRESR1
SCHEMBL27564811 0.78 CNR2 (0.36) CNR2CYP3A4TSHRESR1TDP1
SCHEMBL6627241 0.77 CNR2 (0.38) CNR2CNR1ESR1
Iodide SCHEMBL6628988 0.76 CNR2 (0.37) CNR2
SCHEMBL16631789 0.74 CYP2C9 (0.40) CNR2CYP3A4CA12CA1CA2
SCHEMBL2405699 0.73 TP53 (0.41) CNR2MEN1KMT2ARAB9AKDM4E
SCHEMBL6621875 0.71 MKNK1 (0.43) CYP3A4LMNAKMT2ATSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794387-B2 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (CGMP PDE5) INHIBITORS; 2-(5-ACETYL-2-BUTOXY-3-PYRIDINYL)-7-ETHYL-5-METHYLIMIDAZO(5,1 -F)(1,2,4)TRIAZIN-4(3H)-ONE FOR EXAMPLE PFIZER INC. 2004-09-21 US disclosed
EP-1395589-A1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS Pfizer Limited (GB) 2004-03-10 EP disclosed
EP-1380293-A1 BONE METABOLISM IMPROVING AGENTS The Nisshin OilliO, Ltd. (JP) 2004-01-14 EP disclosed
US-20020177599-A1 Pharmaceutically active compounds PFIZER INC. 2002-11-28 US disclosed
WO-2002079203-A1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS PFIZER LIMITED (GB) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177599-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A CNR2 1534/4885CYP3A4 432/4885LMNA 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.